Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

32 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Trp53 deficiency protects against acute intestinal inflammation.
Spehlmann ME, Manthey CF, Dann SM, Hanson E, Sandhu SS, Liu LY, Abdelmalak FK, Diamanti MA, Retzlaff K, Scheller J, Rose-John S, Greten FR, Wang JY, Eckmann L. Spehlmann ME, et al. J Immunol. 2013 Jul 15;191(2):837-47. doi: 10.4049/jimmunol.1201716. Epub 2013 Jun 14. J Immunol. 2013. PMID: 23772033 Free PMC article.
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Targan SR, et al. Among authors: spehlmann me. Gastroenterology. 2007 May;132(5):1672-83. doi: 10.1053/j.gastro.2007.03.024. Epub 2007 Mar 21. Gastroenterology. 2007. PMID: 17484865 Clinical Trial.
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Sandborn WJ, et al. Among authors: spehlmann me. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021. Epub 2010 May 6. Clin Gastroenterol Hepatol. 2010. PMID: 20451663 Clinical Trial.
32 results